Introduction: Many patients need more than one antihypertensive agent for effective blood
bradycardia, nausea, and skin reactions. Only three AEs were classified as serious. Conclusion: These data from a non-interventional study in a large patient population demonstrate the benefits of prescribing a FDC of bisoprolol-amlodipine in terms of an excellent adherence and an associated improvement in control of previously elevated BP, which may be relevant in real-life practice.
INTRODUCTION
For a number of medical research questions, the results produced by the ''gold standard'' of clinical research-randomized, double-blind, controlled trials (RCTs) of drugs or medical applications-are limited in the evidence they provide regarding potential applications and effects, risks, and patient adherence in a routine medical setting [1, 2] . Without diminishing the importance and necessity of RCTs in documenting the efficacy and safety of medicinal products, there is a consensus that additional data are required from studies in patients whose diagnosis, treatment, and monitoring exclusively follow normal medical practice [3] , while the patients involved benefit from the increased therapeutic freedom versus participation in a RCT. Carefully planned, conducted, and evaluated non-interventional studies may be particularly useful in drawing conclusions regarding the effects, safety, and-in some cases-acceptance following the approval of a new drug-and study design guidelines are now available [4] .
Systematic analysis of data from RCTs versus non-interventional studies has shown virtually no evidence of superiority of RCTs in terms of assessing the effects of medicinal products [5] . This conclusion applies regardless of the specific design, study population criteria, and data acquisition periods.
Non-interventional studies are conducted in various designs. One such format is a cohort study, in which participants undergo specific medical care and their outcome is monitored and evaluated at certain times [1, 6, 7] . A prerequisite is that the expected effects in real-life conditions are largely similar to those investigated in RCTs and that the investigating sites are qualified to use the investigational material. This helps to minimize the dropout rate. Non-interventional studies of this kind generally involve large sample sizes and may therefore help to identify rare adverse events (AEs).
Event Clinical trial results show that a very large proportion of patients receiving antihypertensive treatment from primary care physicians do not achieve these recommended BP levels [11, 12] . Many patients require more than one antihypertensive drug for successful BP control [13, 14] [17] [18] [19] and produced a significant reduction in previously elevated BP at the respective dose levels employed. The FDCs also achieved better results than regimens based on a free-dose combination of the two agents.
To produce additional evidence for these FDCs, an extensive non-interventional study was conducted involving two chronologically separate periods. The first part of the study was evaluated after 4288 patients had been enrolled and treated for 6 months [20] . Monitoring of the percentage of tablets taken at 6 months revealed a very high rate of good to excellent adherence ([95%). At the same time, a clinically relevant decline in previously elevated BP was noted (systolic 15%, diastolic 11%), although most patients had been receiving the same doses of bisoprolol and amlodipine in a free combination.
To further verify the accuracy of these results, the study was continued at the same sites, and a number of new sites were added to include results for around 10,000 patients. This enabled data from the first study period to be checked against the data for the whole of this non-interventional study.
METHODS
The plan for this non-interventional study Access to patient data was restricted exclusively to the investigators. All patients were assigned an ID number before the study to enable anonymous documentation for evaluation purposes. Patients were informed about these data protection measures at the start of the study and asked to sign a consent form to participate in accordance with the conditions described. All procedures followed were in accordance with the ethical standards of the responsible committee on human 
RESULTS
This multicenter non-interventional study included 10,532 patients who were treated in 68 Polish centers. The demographic data of the patients are summarized in Table 1 Prior to the switch to the FDC, all patients had been pretreated with a free combination of bisoprolol (mean 5.5 mg once daily) and amlodipine (mean 6.1 mg once daily). The lowest possible dose (5 mg bisoprolol and 5 mg amlodipine once daily) was prescribed for the majority of patients (75%); data in Table 1 show that most patients did not reach the target value for systolic BP below 140 mmHg. The average dose in the FDC after switching from the free dose was 5.8 ± 2 mg bisoprolol and 6.4 ± 3 mg amlodipine once daily. In this respect, the switch to the FDC was only associated with The analysis of data for BP control showed a clinically relevant regression of systolic and diastolic values, although no considerable dose changes were made during the study period (Table 3) . BP was measured in a supine position after at least 5 min of rest. Figure 1 shows the proportion of patients with systolic BP changes after 6 months of FDC treatment. It is noteworthy that BP reductions were confirmed for all drug doses tested (Table 4) . Accordingly, remarkable differences can be registered regarding the proportions of patients per quartile between the values at study start and after 6 month if the subdivision of quartiles at study start is maintained (Fig. 2) . The reductions in diastolic BP were very similar to the reductions in systolic BP shown in Fig. 2 .
There was a noticeable correlation between BP values prior to the study and the extent of their decline (r 0.8).
The importance of adherence for good BP control becomes particularly evident when
comparing BP values as a function of patient's behavior. Although only 2% of patients showed moderate or poor adherence, their BP measurements were remarkably higher than those of patients with good to excellent adherence ( Table 5 ). The benefits of adherence on BP control are confirmed by the improvement in pulse pressure by an average of 58.7 mmHG ± 13 (median 60) at study start versus 51.7 mmHg ± 11 (median 50) after 6 months of treatment. All patients were asked whether they would choose the free combination or the FDC; approximately 97% of patients preferred the FDC.
Although all patients had been treated with a free-dose combination of bisoprolol and amlodipine and switched to the FDC at least 4 weeks before starting the study, BP measurement at study start showed differences in systolic readings, which were attributable to the respective comorbidities (Table 6 ). In contrast, patients who reported none of the listed comorbidities had a lower systolic BP (average 145 ± 10 mmHg). Another improvement observed during the study was a considerable reduction in heart rate from an average of 75 ± 10 to 68.6 ± 10 bpm, which can also help to reduce the health risk for these patients.
Safety Evaluation
In total, 89 AEs were reported in 70 patients (0.7%). The majority of these were edema (41, 46.1%), headache (7, 7.8%), dizziness (6, 6.7%), and bradycardia, nausea, and skin burning/ redness (4, 4.5% each). Only three AEs (3.4%) were considered serious, one case of atrial fibrillation (not related), one case of chronic heart failure worsening, and one head injury leading to death (not related). Just nine patients (0.09%) discontinued the study due to AEs, including lower limb or ankle swelling or other edema, nausea/malaise, skin burning/redness/ [21] .
The most important goal of treatment is to manage hypertension and to deal with the other identified risk factors for cardiovascular disease. For hypertension, the treatment goal for systolic BP is usually \140 mmHg and for diastolic BP \90 mmHg. Most patients will require more than one drug to efficiently control their BP. The choice of drugs will be influenced by many different aspects and conditions (e.g., diabetes and coronary disease). Generally, there are many clinically proven recommendations for drug selection either for patients whose primary problem is hypertension, or for patients who have a major comorbidity associated with their hypertension. As regards calcium channel blockers, most experience with these agents has been gained with the dihydropyridines, such as amlodipine and nifedipine, which have shown beneficial effects on cardiovascular and stroke outcomes in hypertension trials [22] . Beta-blockers reduce cardiac output and decrease the release of renin from the kidney. They have strong clinical outcome benefits in patients with histories of myocardial infarction and heart failure and are effective in the management of angina pectoris [23, 24] . However, patients find having to take a large number of tablets burdensome [24] . This manifests itself in non-compliance with treatment as directed, or discontinuation of treatment [25] . Failure of hypertensive treatment is demonstrably attributable mainly to poor adherence to treatment on the part of patients [26] . European guidelines for the management of hypertension accordingly recommend treatment with a combination tablet [10] and the results of various studies indicate the clinical relevance of this recommendation [25, 27, 28] .
The study results available to date demonstrate the relationship between successful BP management and patient adherence, in particular since the results from the first study period in more than 4000 patients corresponded fully to those generated in the total population of more than 10,000 patients [20] .
The cohort recruited in this study can be considered as representative of real-life hypertension treatment. The study covered a wide range of ages: 23% of patients were aged \50 years and 15% were aged [70 years, thus, most patients were aged between 50 and 70 years. Good to excellent adherence was Comparison of results of the preceding study with those of the overall group identified no differences in the changes in BP, which is an indication of rigorous and meticulous project conduct. The results do not contradict those obtained in investigational controlled trials [18, 19] . To that extent, the results of this non-interventional study tend to contradict the commonly postulated study design hierarchy and confirm the insights of other authors on this subject [29, 30] .
Beyond that, this non-interventional study provides insights into additional factors in the lives of hypertension patients, in particular with regard to their comorbidities and treatment outcomes in these circumstances while receiving routine medical care. The absence of strict inclusion criteria, such as apply in RCTS, enables data to be collected from patients with a variety of comorbidities that may have a meaningful impact on their condition and may constitute additional risks. 
